PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,764,559 | -72.6% | 285,645 | -54.6% | 0.00% | -66.7% |
| Q2 2023 | $17,377,510 | -13.0% | 629,164 | -27.6% | 0.00% | -40.0% |
| Q1 2023 | $19,982,032 | +216.7% | 868,784 | +50.2% | 0.01% | +400.0% |
| Q4 2022 | $6,308,500 | +63.6% | 578,231 | +26.4% | 0.00% | – |
| Q3 2022 | $3,857,000 | +67.8% | 457,588 | +57.6% | 0.00% | – |
| Q2 2022 | $2,298,000 | -49.5% | 290,360 | +51.1% | 0.00% | – |
| Q1 2022 | $4,550,000 | -91.6% | 192,154 | -87.8% | 0.00% | -100.0% |
| Q4 2021 | $53,878,000 | +194.4% | 1,575,426 | +52.5% | 0.00% | -33.3% |
| Q3 2021 | $18,303,000 | +485.7% | 1,032,883 | +1383.3% | 0.00% | – |
| Q2 2021 | $3,125,000 | +27.6% | 69,633 | -26.4% | 0.00% | – |
| Q1 2021 | $2,450,000 | -19.1% | 94,634 | -37.0% | 0.00% | – |
| Q4 2020 | $3,030,000 | +1283.6% | 150,306 | +1239.6% | 0.00% | – |
| Q3 2020 | $219,000 | -63.6% | 11,220 | -76.5% | 0.00% | – |
| Q1 2019 | $601,000 | +489.2% | 47,788 | +214.2% | 0.00% | – |
| Q4 2018 | $102,000 | – | 15,208 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |